Innovent Bio

Developer of antibody therapeutics for multiple diseases

placeSuzhou, Jiangsu, China calendar_todayFounded 2011 groups5,144 employees language innoventbio.com

Social engagement

Social engagement: 34.7K social following, 10 posts in the last 12 months — below the industry typical range.

Investor mix

26 investors on record; lead investors include F-Prime Capital, Legend Capital, Lilly Asia Ventures, Eight Roads Ventures; 1 has since exited.

Investor typeCountShare
Venture capital1038%
Private equity623%
Other / undisclosed1038%

Recent activity

1 Jul 2026
Partnership
Lilly
9 Jun 2026
Event
ADA2026
Coming soon